Louise Barys

Polyclonal Secondary <i>FGFR2</i> Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma

Lipika Goyal, Supriya K. Saha, Leah Y. Liu et al. · Cancer Discovery · 2016 · 545 citations · Full text

Medicine, Molecular Biology, Oncology +17

FGFR Genetic Alterations Predict for Sensitivity to NVP-BGJ398, a Selective Pan-FGFR Inhibitor

Vito Guagnano, Audrey Kauffmann, Simon Wöhrle et al. · Cancer Discovery · 2012 · 364 citations · Full text

Medicine, Molecular Genetics, Oncology +17

Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition

Madlaina Breuleux, Matthieu Klopfenstein, Christine Stephan et al. · Molecular Cancer Therapeutics · 2009 · 241 citations · Full text

Medicine, Oncology, Pharmacology +14

Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C

Andreas Weiss, Edwige Lorthiois, Louise Barys et al. · Cancer Discovery · 2022 · 134 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +13

Comprehensive Mapping of p53 Pathway Alterations Reveals an Apparent Role for Both SNP309 and <i>MDM2</i> Amplification in Sarcomagenesis

Moriko Ito, Louise Barys, Terence O’Reilly et al. · Clinical Cancer Research · 2010 · 112 citations

Medicine, Genetics, Oncology +17